Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients

Prospective Study ofPhoton Counting Computed Tomography in Acute Coronary Syndrom Patients

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07536607

Enrollment

180

Registered

2026-04-17

Start date

2026-04-20

Completion date

2028-12-01

Last updated

2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

photon-counting detector CT, coronary artery disease

Brief summary

For patients with severe calcification or complex non-calcified plaques, we investigate wether PCCT can enable non-invasive, in vivo precise differentiation and quantitative measurement of plaque components (e.g., spotty calcification, necrotic core, fibrous tissue). Further we also study wether these quantitative imaging features can independently predict the risk of MACE in the short term and long term

Detailed description

Photon-counting detector CT (PCD-CT), as an innovative technology in the field of CT imaging, is gradually transforming the landscape of cardiac imaging. It differs significantly from conventional energy-integrating detector CT (EID-CT) in technical principles, bringing new possibilities for the diagnosis and assessment of heart diseases. This study will enrolled patients undergo standardized PCCT coronary angiography (CCTA) and make ultra-fine quantitative plaque analysis. Then at least 12 months of clinical follow-up will be performed. Finally correlation analysis between baseline plaque characteristics and follow-up endpoint events will be made.

Interventions

OTHERthere is no intervention in this study

there is no intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Inclusion Criter: * Adult patients (≥18 years) with clinically diagnosed coronary artery disease or undergoing CCTA for chest pain/heart failure symptoms. * Able and willing to provide informed consent and complete scheduled follow-up visits.

Exclusion criteria

* History of iodine contrast agent allergy. * Severe renal insufficiency (eGFR \< 30 mL/min/1.73 m²). * History of prior coronary artery bypass grafting (CABG). * Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame	Description
Major Adverse Cardiovascular Events, MACE	12months	Non-fatal myocardial infarction Non-fatal stroke Cardiovascular death Revascularization Acute heart failure

Countries

China

Contacts

CONTACTjing ma, PhD, MD, PhD,MD

crystalma@126.com+86 13681257396

PRINCIPAL_INVESTIGATORJing ma, PhD,MD

Chinese PLA General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026